Pursing International Market Opportunities for the Company's Medical

                              Countermeasures



    ANNAPOLIS, Md., Aug. 11 /EMWNews/ -- PharmAthene, Inc.

(Amex: PIP), a biodefense company developing medical countermeasures

against biological and chemical threats, today announced that Lord Lewis

Moonie has joined the Company as a special UK government advisor.



    Lord Moonie will assist PharmAthene in exploring interest and support

for the Company's biodefense programs and product candidates within the UK

government.



    "We are honored to welcome Lord Moonie to PharmAthene in this advisory

capacity and are delighted to have the opportunity to leverage his

significant knowledge of the UK biodefense industry and amongst our NATO

allies," stated David P. Wright, President and Chief Executive Officer of

PharmAthene. "Lord Moonie's medical background and extensive experience as

a Member of Parliament, as well as his oversight of the Research

Establishment at Porton Down, which included recombinant vaccines for

plague and anthrax, will be invaluable to us as we continue to expand

awareness and the market for our biodefense countermeasures among our

Allies. We view Lord Moonie's appointment as an important step in the

execution of our international strategy to meet the urgent needs of nations

internationally requiring medical countermeasures."



    Lord Moonie retired from the UK's House of Common in 2005 after

eighteen years as Member of Parliament for Kirkcaldy. During this time,

Lord Moonie spent three and a half years as a junior minister in the

Ministry of Defence (MOD), with responsibility for all of MOD's Science and

Technology, including the Defence Diversification Agency. Prior to this he

was a consultant in public health medicine in the NHS. Following his

service in the MOD, Lord Moonie was chairman of a pre-legislative committee

of both the House of Commons and House of Lords which scrutinized the draft

Civil Contingencies Bill.



    Since 2004, Lord Moonie has served as a non-executive director of AEA

Technology, which provides a wide range of consultancy and advisory

services, and program management to government in the fields of energy

management and the environment.



    Lord Moonie is a member of the Board of Trustees of the charity

Skillforce, and is a consultant in a variety of fields, including energy,

health services and communications. He currently sits on the European

Advisory Board of Northrop Grumman and is a non-executive director of Party

Gaming.

    About PharmAthene, Inc.



    PharmAthene was formed to meet the critical needs of the United States

and its allies by developing and commercializing medical countermeasures

against biological and chemical weapons. PharmAthene's lead product

development programs include:



    -- SparVax(TM) -- a second generation recombinant protective antigen

(rPA) anthrax vaccine



    -- Valortim(R) -- a fully human monoclonal antibody for the prevention

and treatment of anthrax infection



    -- Protexia(R) -- a novel bioscavenger for the prevention and treatment

of morbidity and mortality associated with exposure to chemical nerve

agents



    -- RypVax(TM) -- a recombinant dual antigen vaccine for plague a third

generation rPA anthrax vaccine.



    For more information about PharmAthene, please visit

http://www.PharmAthene.com.



    Statement on Cautionary Factors



    Except for the historical information presented herein, matters

discussed may constitute forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995 that are subject to

certain risks and uncertainties that could cause actual results to differ

materially from any future results, performance or achievements expressed

or implied by such statements. Statements that are not historical facts,

including statements preceded by, followed by, or that include the words

"potential"; "believe"; "anticipate"; "intend"; "plan"; "expect";

"estimate"; "could"; "may"; "should"; or similar statements are

forward-looking statements. PharmAthene disclaims, however, any intent or

obligation to update these forward-looking statements. Risks and

uncertainties include risk associated with the reliability of the results

of the studies relating to human safety and possible adverse effects

resulting from the administration of the Company's product candidates,

unexpected funding delays and/or reductions or elimination of U.S.

government funding for one or more of the Company's development programs,

unforeseen safety issues, unexpected determinations that these product

candidates prove not to be effective and/or capable of being marketed as

products, as well as risks detailed from time to time in PharmAthene's

public disclosure filings with the U.S. Securities and Exchange Commission

(the "SEC"). Furthermore, there can be no assurance that our engagement of

Lord Moonie will result in the award of any contracts with the UK

government or any ministries, departments, agencies and the like thereof to

PharmAthene. Copies of PharmAthene's public disclosure filings are

available from its investor relations department.